Shots:

• Seed Therapeutics to receive $10M upfront- $10M equity investment- ~$780M as pre/clinical development- regulatory & commercial milestones along with royalties on net sales of products that emerges from the collaboration
• Seed utilizes molecular glue protein degradation technology to develop potential new therapies
• The agreement allows Seed to advance its platform to deliver new molecules targeting proteins that cause human diseases

 ­ Ref: Globe Newswire | Image: Eli Lilly